Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma

A Randomised, Double-Blind Placebo-Controlled Study Assessing the Short-Term Effect of a Dermatophagoides Pteronyssinus Extract, Quantified in Mass Units, in Subjects With Perennial Mite Induced Asthma

The purpose of this study is to determine whether a short course of subcutaneous immunotherapy is efficacious in mite induced asthma. The efficacy is based on reduction in control medication.

The control of mild-moderate persistent asthma include the need of concomitant medication, as inhaled corticosteroids. However, compliance in perennial asthma is low. The aim of this study is to assess the possibility to reduce the need of concomitant medication through a short-course of subcutaneous immunotherapy.

Inclusion Criteria:

• Mild/moderate persistent asthma
• Positive skin prick test or specific IgE to mites
• Age: 14-55 years old

Exclusion Criteria:

• Immunotherapy contraindications
• Allergy to other inhalant allergens
• Previous immunotherapy (5 years)with mites